194 related articles for article (PubMed ID: 20128552)
1. Clinical and histologic ocular findings in pompe disease.
Yanovitch TL; Banugaria SG; Proia AD; Kishnani PS
J Pediatr Ophthalmol Strabismus; 2010; 47(1):34-40. PubMed ID: 20128552
[TBL] [Abstract][Full Text] [Related]
2. Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.
Prakalapakorn SG; Proia AD; Yanovitch TL; DeArmey S; Mendelsohn NJ; Aleck KA; Kishnani PS
J Pediatr Ophthalmol Strabismus; 2014; 51(6):355-62. PubMed ID: 25139343
[TBL] [Abstract][Full Text] [Related]
3. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
[No Abstract] [Full Text] [Related]
4. Ptosis, extraocular motility disorder, and myopia as features of pompe disease.
Slingerland NW; Polling JR; van Gelder CM; van der Ploeg AT; Bleyen I
Orbit; 2011 Mar; 30(2):111-3. PubMed ID: 21438734
[TBL] [Abstract][Full Text] [Related]
5. Ptosis in Pompe disease: common genetic background in infantile and adult series.
Ravaglia S; Bini P; Garaghani KS; Danesino C
J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
[No Abstract] [Full Text] [Related]
6. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
7. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
Kishnani PS; Beckemeyer AA; Mendelsohn NJ
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapy.
Pardo J; García-Sobrino T; López-Ferreiro A
J Neurol Sci; 2015; 353(1-2):181-2. PubMed ID: 25911022
[No Abstract] [Full Text] [Related]
9. Dilated Cerebral Arteriopathy in Classical Pompe Disease: A Novel Finding.
Viamonte M; Tuna I; Rees J
Pediatr Neurol; 2020 Jul; 108():117-120. PubMed ID: 32248988
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment of myogenic blepharoptosis.
De Wilde F; D'Haens M; Smet H; Martin JJ; Tassignon MJ
Bull Soc Belge Ophtalmol; 1995; 255():139-46. PubMed ID: 7496569
[TBL] [Abstract][Full Text] [Related]
11. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
Case LE; Beckemeyer AA; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
13. Prominent vacuolation of the eyelid levator muscle in an early-treated child with infantile-onset Pompe disease.
Chien YH; Lee NC; Tsai YJ; Thurberg BL; Tsai FJ; Hwu WL
Muscle Nerve; 2014 Aug; 50(2):301-2. PubMed ID: 24706590
[No Abstract] [Full Text] [Related]
14. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
Tan QK; Cheah SM; Dearmey SM; Kishnani PS
Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
[TBL] [Abstract][Full Text] [Related]
15. How to describe the clinical spectrum in Pompe disease?
Güngör D; Reuser AJ
Am J Med Genet A; 2013 Feb; 161A(2):399-400. PubMed ID: 23300052
[No Abstract] [Full Text] [Related]
16. Nystagmus in Infantile Pompe Disease: a new feature?
Turco EC; Facini C; Piccolo B; Pisani F
Acta Biomed; 2020 Sep; 91(3):e2020083. PubMed ID: 32921779
[TBL] [Abstract][Full Text] [Related]
17. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.
Higuchi T; Kawagoe S; Otsu M; Shimada Y; Kobayashi H; Hirayama R; Eto K; Ida H; Ohashi T; Nakauchi H; Eto Y
Mol Genet Metab; 2014 May; 112(1):44-8. PubMed ID: 24642446
[TBL] [Abstract][Full Text] [Related]
18. New insights into therapeutic options for Pompe disease.
Richard E; Douillard-Guilloux G; Caillaud C
IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
[TBL] [Abstract][Full Text] [Related]
19. Perioperative management of children with glycogen storage disease type II-Pompe disease.
Bosman L; Hoeks SE; González Candel A; van den Hout HJM; van der Ploeg AT; Staals LM
Paediatr Anaesth; 2018 May; 28(5):428-435. PubMed ID: 29575534
[TBL] [Abstract][Full Text] [Related]
20. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature.
Hobson-Webb LD; Proia AD; Thurberg BL; Banugaria S; Prater SN; Kishnani PS
Mol Genet Metab; 2012 Aug; 106(4):462-9. PubMed ID: 22664150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
